Shanmugam Muthusamy's Form 4 filing

Ani Pharmaceuticals Inc (ANIP) · filed Aug 30, 2023

Accession no.: 0001870913-23-000005
Filed: Aug 30, 2023
Trade date: Aug 28-29, 2023
Filing delay: 2 days
Rule 10b5-1 plan: Not checked

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $3.16M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Shanmugam MuthusamyCIK 0001870913	Director, Officer (HEAD OF R&D, COO-NOVITIUM OPS)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Aug 28, 2023	Common Stock	SSaleDisposed	−25,000	$63.06^F1	−$1,576,500	1,157,620	Indirect
Aug 29, 2023	Common Stock	SSaleDisposed	−25,000	$63.37^F3	−$1,584,250	1,132,620	Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

Reflects the weighted average price of sales on August 28, 2023. The shares were sold in multiple transactions at prices ranging from $62.57 to $64.64, inclusive.

Referenced by the price of 1 transaction in Table I.

Reflects the weighted average price of sales on August 29, 2023. The shares were sold in multiple transactions at prices ranging from $62.4877 to $63.92, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)